{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:12:42Z","timestamp":1773421962761,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T00:00:00Z","timestamp":1069286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold><jats:sc>objective<\/jats:sc>\u2002<\/jats:bold> A dose\u2013response study with different doses of dexamethasone (dex) to assess the corticotrophic resistance in Cushing's disease (CD) using salivary cortisol as an end point has not yet been evaluated. We also reported our experience with salivary cortisol compared to plasma cortisol determination during dex suppression test (DST) and after ovine corticotrophin release hormone (oCRH) test in the differential diagnosis of Cushing's syndrome (CS).<\/jats:p><jats:p><jats:bold><jats:sc>design<\/jats:sc>\u2002<\/jats:bold> We studied 46 patients with CS, including 28 patients with CD, 16 with adrenal disease and two with occult ectopic adrenocorticotropic hormone (ACTH) tumours. Salivary cortisol was compared to plasma cortisol and ACTH during a DST 2\u00a0mg for 2\u00a0days, 8\u00a0mg for 2\u00a0days and 24\u00a0mg for 1\u00a0day, and after oCRH test.<\/jats:p><jats:p><jats:bold><jats:sc>results<\/jats:sc>\u2002<\/jats:bold> We observed a dose\u2010dependent suppression of salivary cortisol, plasma cortisol and ACTH in CD patients. Salivary cortisol presented a higher percentage of suppression than plasma cortisol: 42%<jats:italic>vs.<\/jats:italic> 15% (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b7002), 82%<jats:italic>vs.<\/jats:italic> 67% (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b7002) and 90%<jats:italic>vs.<\/jats:italic> 83% (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b703) after 2, 8 and 24\u00a0mg\/day dex, respectively. The lowest percentage of suppression was observed for plasma ACTH. The parallelism of these lines identified that the criterion of 65% suppression of salivary cortisol corresponding to 50% suppression of plasma cortisol after 8\u00a0mg\/day for 2\u00a0days is consistent with CD. The sensitivity and specificity using 50% suppression for plasma cortisol were 81% and 83%, respectively, for 8\u00a0mg DST. Using the criterion of 65% suppression of salivary cortisol, the sensitivity and specificity were 86% and 100%, respectively, for 8\u00a0mg DST. After oCRH test the sensitivity and specificity were 86% and 91%, respectively, for ACTH, 100% and 64%, respectively, for plasma cortisol and 93% and 91%, respectively, (20% of increment) or 86% and 100%, respectively, (35% increment) for salivary cortisol.<\/jats:p><jats:p><jats:bold><jats:sc>conclusion<\/jats:sc>\u2002<\/jats:bold> In conclusion, salivary cortisol presents more profound suppression than plasma cortisol or ACTH in a dose\u2013response pattern after different doses of dex in patients with CD. In addition, our data suggest that measurement of salivary cortisol might improve the DST as compared to plasma cortisol in the differential diagnosis of CS.<\/jats:p>","DOI":"10.1046\/j.1365-2265.2003.01908.x","type":"journal-article","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T03:47:46Z","timestamp":1069386466000},"page":"800-805","source":"Crossref","is-referenced-by-count":33,"title":["A dose\u2013response study of salivary cortisol after dexamethasone suppression test in Cushing's disease and its potential use in the differential diagnosis of Cushing's syndrome"],"prefix":"10.1111","volume":"59","author":[{"given":"Margaret","family":"Castro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucila L. K.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula C. L.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayrton C.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,11,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00345.x"},{"key":"e_1_2_6_3_1","first-page":"478","volume-title":"The Pituitary","author":"Bertagna X.","year":"1995"},{"key":"e_1_2_6_4_1","first-page":"158","article-title":"Nocturnal high\u2010dose dexamethasone suppression test in the aetiological diagnosis of Cushing's syndrome","volume":"109","author":"Bruno O.D.","year":"1985","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.3.878"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5160.1117"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(79)90097-0"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30081-1"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-3-211"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-20-12-1539"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.12.5711"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(85)90232-3"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1999.00749.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1993.tb01756.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.19.5.647"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.77.5.1308"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199109263251301"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199109263251309"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019616-200010010-00004"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.8.2681"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1996.645466.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-104-2-180"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1980.tb01376.x"},{"key":"e_1_2_6_24_1","first-page":"292","volume-title":"Biostatistical Analysis","author":"Zar J.H.","year":"1984"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.2003.01908.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.2003.01908.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.2003.01908.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T16:41:06Z","timestamp":1697215266000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.2003.01908.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,20]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1046\/j.1365-2265.2003.01908.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.2003.01908.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11,20]]}}}